Comparing the current results to its competitors, Precipio Inc reported Revenue increase in the 2 quarter 2026 by 24.18 % year on year. The sales growth was above Precipio Inc 's competitors' average revenue growth of 19.34 %, achieved in the same quarter.
Precipio Inc 's Comment on Competition and Industry Peers
The clinical pathology services market is segmented into two primary groups. The first group comprises companies specializing in oncology diagnostics, including NeoGenomics Laboratories, Inc. (also known as NeoGenomics or Neo), GenPath Diagnostics, and Inform Diagnostics. The second group consists of large commercial laboratories offering a wide range of tests, such as LabCorp and Quest Diagnostics. In the liquid biopsy sector, competitors include Foundation Medicine and Guardant Health. Within the Products division, competition arises from various reagent manufacturers producing similar products. Several competitors possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing, which may enable them to secure FDA or other regulatory approvals more quickly and establish stronger market positions.
February 6, 2024
Driven by a commitment to provide patients with precise diagnostic tools, the specialty cancer diagnostics firm Precipio, Inc. (NASDAQ: PRPO) has made a landmark announcement. Precipio recently inked a distribution agreement with Cardinal Health, bridging the gap between advanced cancer diagnostics and patients worldwide. This significant partnership holds great potential for furthering the cause of cancer detection and treatment.Precipio, a trailblazer in the field of cancer diagnostics focusing on delivering accurate and quick diagnostic outcomes, has carved its niche in personalized medicine. Its HemeScreen portfolio of molecular assays has emerged as a game-changer in cancer diagnostics. Unveiling the es...
January 17, 2024
In a major breakthrough, Precipio, a global diagnostics company specializing in the field of cancer diagnostics, has recently signed a distribution agreement for its innovative IV-Cell and HemeScreen technologies in Japan. This agreement marks a crucial milestone for Precipio and positions the company to tap into the Japanese market, known for its high-quality healthcare infrastructure and cutting-edge research activities. Additionally, the company has received its first order for IV-Cell from a leading Japanese laboratory, further emphasizing the growing demand for Precipio s groundbreaking solutions.Expanding Presence in Japan:Precipio s foray into the Japanese market has been strategically planned to leve...
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Veracyte Inc's business model revolves around providing genomic diagnostic solutions to enable physicians to make more informed treatment decisions for patients.
Sources:
Precipio inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Precipio inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
